Cingulate Inc. (CING)
Dopo ore:
| Chiusura precedente | 0,9608 |
| Aperto | 1,0000 |
| Denaro | 0,0000 x 1000 |
| Lettera | 0,0000 x 1000 |
| Min-Max giorno | 0,9503 - 1,0000 |
| Intervallo di 52 settimane | 0,6640 - 2,2000 |
| Volume | |
| Media Volume | 52.916 |
| Capitalizzazione | 10,97M |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,1560 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,00 |
- GlobeNewswire
Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD
Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the initiation of the first Phase 3 clinic
- GlobeNewswire
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer, PharmD, will participate in a live Benzinga All Access event on Friday December 16, 2022, at 9:20 a.m. CST. The appearance had previously been scheduled for Friday
- GlobeNewswire
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Friday December 2, 2022, at 10 a.m. CST. The discussion will address the current unmet needs in Attention De
